Stockreport
BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
Morgan Healthcare Conference to outline strategic priorities for 2026, provide preliminary 2025 revenue figures, and highlight a slate of upcoming regulatory and clinical catalysts. Chief Executive Officer Alexander Hardy said the company has been “transforming BioMarin” over the past 24 months and is targeting an additional period of growth driven by Voxzogo, its enzyme therapies portfolio, and the pending acquisition of Amicus. Hardy framed BioMarin's strategy around three pillars introduced at the company's September 2024 Investor Day: innovation, growth, and a “value commitment” focused on operating leverage. He said BioMarin has prioritized pipeline programs it views as having the most transformative potential and pointed to accelerated progress for two pipeline assets, BMN 333 and BMN 351. ? NVIDIA's Next Leg Higher May Have Started at CES 3 Oversold Stocks with Big RSI Rebound Potential For 2026, Hardy said BioMarin's priorities are to: Accelerate revenue by expanding
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "buy" rating. They now have a $98.00 price target on the stock, up previously from $84.00.[MarketBeat]
- Making U.S. biotech more competitive with China's could help rare disease patients, experts say [CNBC][CNBC]
- Does BioMarin Pharmaceutical (BMRN) Price Weakness Contrast With Its Cash Flow Valuation? [Yahoo! Finance][Yahoo! Finance]
- BMRN or TARS: Which Is the Better Value Stock Right Now? [Yahoo! Finance][Yahoo! Finance]
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer [Yahoo! Finance][Yahoo! Finance]
- More
BMRN
SEC Filings
SEC Filings
- 1/12/26 - Form 8-K
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- BMRN's page on the SEC website
- More